ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Genentech will collaborate with Ribometrix to discover and develop small molecules that target 3-D structures in RNA. Ribometrix was cofounded by Kevin Weeks, a chemist at the University of North Carolina at Chapel Hill, based on chemical-probing techniques he invented to determine the structures of RNA. The firm is one of several start-ups hoping to prove that small molecules can tackle RNA. It will earn $25 million up front and up to $1 billion in milestones.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter